Navigation Links
ev3 Inc. Reports Third Quarter 2008 Financial Results
Date:10/31/2008

ion and non-cash stock-based compensation of $3.1 million.

Palmisano concluded, "Our top priority is to achieve sustained profitability, so I was particularly pleased with our continued earnings progress and an increase of $7.2 million in our cash and cash equivalents balance compared to the end of the second quarter of 2008. For the remainder of 2008, our focus will be on improving execution and optimizing our cost structure to balance the investment we need to build our business and deliver profitable growth and value to our shareholders. We believe that our efforts to bring innovative, breakthrough endovascular treatments to physicians and patients around the world will create a foundation for continued long-term growth and future profitability."

Third Quarter Business Highlights

During the third quarter of 2008, ev3 reported the following business highlights:

-- Submitted 510(k) applications to the U.S. Food & Drug Administration for EverCross and NanoCross PTA balloons;

-- Reported positive 12-month follow-up results for the European DURABILITY I clinical study, a landmark peripheral stent study covering the longest lesion lengths in a challenging patient population;

-- Announced DEFINITIVE clinical trial series to expand the clinical evidence supporting the value of the SilverHawk and RockHawk Plaque Excision Systems to drive increased procedure adoption, expand clinical indications and support the use of atherectomy as a front-line therapy; and

-- Enrolled first patient in DEFINITIVE Ca++ U.S. IDE trial to evaluate RockHawk Plaque Excision System when used in conjunction with the SpiderFX Embolic Protection Device in the treatment of moderate to heavily calcified peripheral artery lesions.

Sales Review

Peripheral vascular segment product sales in the third quarter of 2008 increased 73% to $66.9 million versus $38.7 million in the third quarter of 2007. On a non-GAAP basis, excluding atherectomy re
'/>"/>

SOURCE ev3 Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20

Related biology technology :

1. eResearchTechnology Reports Third Quarter 2008 Results
2. Thoratec Reports 44 Percent Increase in Third Quarter Revenues
3. Idenix Pharmaceuticals Reports Third Quarter and Nine Month Financial Results
4. Pharmacyclics Reports First Quarter Fiscal 2009 Financial Results
5. Mylan Reports Adjusted Diluted EPS of $0.23 for the Quarter Ended Sept. 30, 2008
6. Vanda Pharmaceuticals Reports Third Quarter 2008 Results
7. United Therapeutics Reports Third Quarter 2008 Financial Results
8. BioMed Realty Trust Reports Third Quarter 2008 Financial Results
9. Varian, Inc. Reports Strong Fourth Quarter 2008 Results
10. Sangamo BioSciences Reports Third Quarter 2008 Financial Results
11. VNUS Medical Technologies Reports Third-Quarter 2008 Results: 25% Growth in Net Product Revenues and 29% Growth in Unit Sales Over Third Quarter 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/13/2014)... Boehringer Laboratories Inc., with a forty ... announce the successful broadcast of a live surgery by ... MD, FACS, FAMBS, and Maher El Chaar, MD, FACS, ... , This sleeve gastrectomy surgery was performed and ... four hundred surgeons from around the world during the ...
(Date:9/12/2014)... , Sept. 12, 2014   Arthur Kay ... bio-bean, has won the Postcode Lottery Green Challenge 2014. ... Kay euro 500,000 ($680,000 USD) at the final in ... business plan. Kay,s company uses a ... biofuel products, namely biodiesel and biomass pellets, used for ...
(Date:9/12/2014)... 2014 Research and Markets has ... Photoresist Industry Report 2014" report to their offering. ... Report 2014 is a professional and in-depth study on ... industry . The report provides a basic ... industry chain structure. The dry film photoresist market analysis ...
(Date:9/12/2014)... LONDON , September 12, 2014 ... 4,591.81, up 0.12%, the Dow Jones Industrial Average finished the ... at 1,997.45, up 0.09%. The gains were broad based as ... The S&P 500 Health Care Sector Index ended the day ... in the last one month. Investor-Edge has initiated coverage on ...
Breaking Biology Technology:Boehringer Laboratories, Inc. Announces Live Surgery Using Innovative System to Calibrate Sleeve Gastrectomy 2Green Startup Bio-Bean Wins $680,000 in Postcode Lottery Green Challenge 2Green Startup Bio-Bean Wins $680,000 in Postcode Lottery Green Challenge 3Global Dry Film Photoresist Industry Report 2014 2Technical Coverage on Biotech Stocks - Exelixis, Arena Pharma, Novavax, Dendreon, and Amicus Therapeutics 2Technical Coverage on Biotech Stocks - Exelixis, Arena Pharma, Novavax, Dendreon, and Amicus Therapeutics 3Technical Coverage on Biotech Stocks - Exelixis, Arena Pharma, Novavax, Dendreon, and Amicus Therapeutics 4Technical Coverage on Biotech Stocks - Exelixis, Arena Pharma, Novavax, Dendreon, and Amicus Therapeutics 5
... Australia, January 23, 2012 Ansell Limited ... it has entered into a multi-year agreement with Koreca ... a leading hand protection specialist in Korea. ... Koreca Industries its exclusive distributor of Industrial and New ...
... 23, 2012   BioLife Solutions , Inc. (OTCBB: BLFS), ... hypothermic storage and cryopreservation freeze media ... additional key opinion leaders in the biobanking , ... markets have joined the Company,s Scientific Advisory Board ...
... Scientists at deCODE Genetics and academic ... report the discovery of variants in the human genome ... risk of thyroid cancer.The paper ,Discovery of common variants ... is published today in the online edition of ...
Cached Biology Technology:BioLife Solutions Adds Clinical and Commercialization Experts to Scientific Advisory Board 2BioLife Solutions Adds Clinical and Commercialization Experts to Scientific Advisory Board 3BioLife Solutions Adds Clinical and Commercialization Experts to Scientific Advisory Board 4BioLife Solutions Adds Clinical and Commercialization Experts to Scientific Advisory Board 5deCODE Genetics, in Collaboration with Academic Colleagues, Discovers Three Variants in the Sequence of the Human Genome that Affect the Risk of Thyroid Cancer 2
(Date:9/16/2014)... PALM BEACH GARDENS, Fla. , Sept. 16, ... provider of biometric identity management solutions, announced today ... handheld solution designed to authenticate the identity of ... The Android-based Verifier Sentry rapidly reads ... the credential holder,s ID by matching the biometric ...
(Date:9/15/2014)... 15, 2014) The so-called central dogma of ... long provided a simplified explanation for how genetic ... , In reality, of course, the process ... articulated nearly 60 years ago by Nobel Laureate ... For one, there are multiple types of RNA, ...
(Date:9/15/2014)... single group of microorganisms may be responsible for much ... with implications for the global carbon cycle and climate ... required by most life on this planet, it is ... because it is so large and complex. For humans, ... brain and nervous systems, as well as DNA synthesis ...
Breaking Biology News(10 mins):Cross Match Launches New Identity Management Handheld Solution 2Scientists discover RNA modifications in some unexpected places 2Researchers discover new producer of crucial vitamin 2
... Researchers at Ume Plant Science Center in Sweden discovered, in ... sugar beets that blocks flowering. Only with the cold of ... to blossom in its second year. The discovery of this ... beets bloom. The new findings were recently published in the ...
... consumed, researchers have learned that up to 90 percent ... the drugs can leave the body almost intact through ... areas, excreted antibiotics can then enter stream and river ... animal feeding operations, fish hatcheries, and nonpoint sources such ...
... Rensselaer Polytechnic Institute assistant professor of chemical and biological ... engineers developing exciting and novel new techniques to treat ... disease, Parkinson,s disease, traumatic brain injury, and brain cancer. ... Goldhirsh Foundation and now has garnered the support of ...
Cached Biology News:New discovery about how flowering time of plants can be controlled 2Virginia Tech engineer identifies new concerns for antibiotic resistance, pollution 2Virginia Tech engineer identifies new concerns for antibiotic resistance, pollution 3Delivering drugs to the brain: New research into targeted treatment of Alzheimer's 2Delivering drugs to the brain: New research into targeted treatment of Alzheimer's 3
Rabbit polyclonal to XPC ( Abpromise for all tested applications). Antigen: Synthetic peptide from N-terminus of Human XPC conjugated to a carrier protein Entrez Gene ID: 7508 Swiss ...
Rabbit polyclonal to FANCG ( Abpromise for all tested applications). Antigen: Synthetic peptide: MSRQTTSVGSSC, corresponding to amino acids 1 - 12 of Human FANCG. Entrez GeneID: 2189 Swis...
Rabbit polyclonal to DcR2 ( Abpromise for all tested applications). entrezGeneID: 8793 SwissProtID: Q9UBN6...
...
Biology Products: